GB0008305D0 - Treatment of fungal infections - Google Patents

Treatment of fungal infections

Info

Publication number
GB0008305D0
GB0008305D0 GBGB0008305.5A GB0008305A GB0008305D0 GB 0008305 D0 GB0008305 D0 GB 0008305D0 GB 0008305 A GB0008305 A GB 0008305A GB 0008305 D0 GB0008305 D0 GB 0008305D0
Authority
GB
United Kingdom
Prior art keywords
treatment
fungal infections
coccidioidomycosis
epitopes
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0008305.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neutec Pharma Ltd
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Priority to GBGB0008305.5A priority Critical patent/GB0008305D0/en
Publication of GB0008305D0 publication Critical patent/GB0008305D0/en
Priority to EP01911971A priority patent/EP1267925B8/en
Priority to DE60128893T priority patent/DE60128893T2/de
Priority to CN01807383A priority patent/CN1420786A/zh
Priority to CNA2007101126651A priority patent/CN101095952A/zh
Priority to CA002401836A priority patent/CA2401836A1/en
Priority to EP07075188A priority patent/EP1818062A3/en
Priority to US10/240,819 priority patent/US20030180285A1/en
Priority to AU4089001A priority patent/AU4089001A/xx
Priority to PCT/GB2001/001195 priority patent/WO2001076627A1/en
Priority to NZ520899A priority patent/NZ520899A/en
Priority to PT01911971T priority patent/PT1267925E/pt
Priority to AU2001240890A priority patent/AU2001240890B2/en
Priority to JP2001574143A priority patent/JP2003530357A/ja
Priority to DK01911971T priority patent/DK1267925T3/da
Priority to RU2002129510/15A priority patent/RU2262952C2/ru
Priority to AT01911971T priority patent/ATE364396T1/de
Priority to EP07075857A priority patent/EP2011512A1/en
Priority to ES01911971T priority patent/ES2287105T3/es
Priority to BR0109846-2A priority patent/BR0109846A/pt
Priority to EP07075462A priority patent/EP1852128A1/en
Priority to PL01358394A priority patent/PL358394A1/xx
Priority to CN200910167220A priority patent/CN101683525A/zh
Priority to NO20024815A priority patent/NO20024815L/no
Priority to CY20071101053T priority patent/CY1106794T1/el
Priority to US11/984,177 priority patent/US20100285029A1/en
Priority to US12/076,643 priority patent/US20080193459A1/en
Priority to US12/076,705 priority patent/US20080181884A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB0008305.5A 2000-04-06 2000-04-06 Treatment of fungal infections Ceased GB0008305D0 (en)

Priority Applications (28)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections
CN200910167220A CN101683525A (zh) 2000-04-06 2001-03-20 β葡聚糖合酶抑制剂与抗HSP90抗体联合治疗真菌感染
AU2001240890A AU2001240890B2 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
DK01911971T DK1267925T3 (da) 2000-04-06 2001-03-20 Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer
CN01807383A CN1420786A (zh) 2000-04-06 2001-03-20 β葡聚糖合酶抑制剂与抗HSP90抗体联合治疗真菌感染
CNA2007101126651A CN101095952A (zh) 2000-04-06 2001-03-20 β葡聚糖合酶抑制剂与抗HSP90抗体联合治疗真菌感染
CA002401836A CA2401836A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
EP07075188A EP1818062A3 (en) 2000-04-06 2001-03-20 An anti HSP90 antibody
US10/240,819 US20030180285A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti hsp90 antibodies
AU4089001A AU4089001A (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
PCT/GB2001/001195 WO2001076627A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
NZ520899A NZ520899A (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti HSP90 antibodies
PT01911971T PT1267925E (pt) 2000-04-06 2001-03-20 Tratamento de infecções fúngicas com anti-fúngicos inibidores de polieno ou beta glucano sintase combinados com anticorpos de hsp90
EP01911971A EP1267925B8 (en) 2000-04-06 2001-03-20 Treatment of fungal infection with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
JP2001574143A JP2003530357A (ja) 2000-04-06 2001-03-20 抗ｈｓｐ抗体と組み合わせたポリエンまたはβグルカンシンターゼインヒビター抗真菌薬での真菌感染症の治療
DE60128893T DE60128893T2 (de) 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti-hsp antikörpern
RU2002129510/15A RU2262952C2 (ru) 2000-04-06 2001-03-20 ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-hsp90-АНТИТЕЛАМИ
AT01911971T ATE364396T1 (de) 2000-04-06 2001-03-20 Behandlung von pilzinfektion mit polyenen oder beta glucan synthese hemmern kombiniert mit anti- hsp antikörpern
EP07075857A EP2011512A1 (en) 2000-04-06 2001-03-20 An anti HSP90 antibody
ES01911971T ES2287105T3 (es) 2000-04-06 2001-03-20 Tratamiento de infecciones micoticas con antimicoticos a base de inhibidor de polieno o betaglucano sintasa combinados con anticuerpos contra hsp90.
BR0109846-2A BR0109846A (pt) 2000-04-06 2001-03-20 Uso de uma composição que compreende um anticorpo ou um fragmento de ligação de antìgeno deste, e conjunto
EP07075462A EP1852128A1 (en) 2000-04-06 2001-03-20 An anti HSP90 antibody
PL01358394A PL358394A1 (en) 2000-04-06 2001-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies
NO20024815A NO20024815L (no) 2000-04-06 2002-10-04 Behandling av soppinfeksjoner med polyen eller beta-glukan syntase-inhibitor anti-sopp midler kombinert med anti HSP90 antistoffer
CY20071101053T CY1106794T1 (el) 2000-04-06 2007-08-07 Θεραπεια μολυνσης απο μυκητα με πολυενιο ή με αντιμυκητιασικα αναστολεα της συνθασης της βητα γλουκανης σε συνδυασμο με αντισωματα αντι hsp90
US11/984,177 US20100285029A1 (en) 2000-04-06 2007-11-14 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies
US12/076,643 US20080193459A1 (en) 2000-04-06 2008-03-20 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti HSP90 antibodies
US12/076,705 US20080181884A1 (en) 2000-04-06 2008-03-21 Treatment of fungal infections with polyene or beta glucan synthase inhibitor anti-fungals combined with anti-hsp90 antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008305.5A GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections

Publications (1)

Publication Number Publication Date
GB0008305D0 true GB0008305D0 (en) 2000-05-24

Family

ID=9889204

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0008305.5A Ceased GB0008305D0 (en) 2000-04-06 2000-04-06 Treatment of fungal infections

Country Status (19)

Country Link
US (4) US20030180285A1 (enExample)
EP (4) EP1852128A1 (enExample)
JP (1) JP2003530357A (enExample)
CN (3) CN101683525A (enExample)
AT (1) ATE364396T1 (enExample)
AU (2) AU2001240890B2 (enExample)
BR (1) BR0109846A (enExample)
CA (1) CA2401836A1 (enExample)
CY (1) CY1106794T1 (enExample)
DE (1) DE60128893T2 (enExample)
DK (1) DK1267925T3 (enExample)
ES (1) ES2287105T3 (enExample)
GB (1) GB0008305D0 (enExample)
NO (1) NO20024815L (enExample)
NZ (1) NZ520899A (enExample)
PL (1) PL358394A1 (enExample)
PT (1) PT1267925E (enExample)
RU (1) RU2262952C2 (enExample)
WO (1) WO2001076627A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050129665A1 (en) * 2002-07-25 2005-06-16 Martin Friedlander Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
EP1457499A1 (en) * 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
US7959915B2 (en) 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
GB0409077D0 (en) 2004-04-23 2004-05-26 Neutec Pharma Plc Treatment of fungal infections
SG153877A1 (en) * 2004-07-02 2009-07-29 Neutec Pharma Plc Treatment of cancer
CN101010100A (zh) 2004-07-02 2007-08-01 纽泰克医药有限公司 癌症的治疗方法
EP1858542A4 (en) * 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
PT2332909E (pt) * 2005-04-13 2014-12-17 Astex Therapeutics Ltd Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90
GB0600168D0 (en) * 2006-01-05 2006-02-15 Neutec Pharma Plc A therapeutic composition
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
US20100113355A1 (en) * 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2008132174A1 (en) * 2007-04-27 2008-11-06 Novartis Ag An immunoglobulin composition
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
CN111116743B (zh) * 2018-10-30 2022-01-28 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
CN111679069A (zh) * 2019-12-31 2020-09-18 安徽中医药大学 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8915019D0 (en) * 1989-06-30 1989-08-23 Matthews Ruth C Medicaments
GB2270076A (en) * 1992-08-18 1994-03-02 Univ Manchester Human HSP 90 Epitopes
US6365165B1 (en) * 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US5834592A (en) * 1995-09-22 1998-11-10 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides

Also Published As

Publication number Publication date
ES2287105T3 (es) 2007-12-16
AU2001240890B2 (en) 2005-06-16
AU4089001A (en) 2001-10-23
US20080181884A1 (en) 2008-07-31
US20030180285A1 (en) 2003-09-25
EP1267925A1 (en) 2003-01-02
NO20024815L (no) 2002-12-02
CN101683525A (zh) 2010-03-31
ATE364396T1 (de) 2007-07-15
US20080193459A1 (en) 2008-08-14
DE60128893D1 (de) 2007-07-26
US20100285029A1 (en) 2010-11-11
NZ520899A (en) 2005-03-24
PT1267925E (pt) 2007-09-04
WO2001076627A8 (en) 2001-11-15
DE60128893T2 (de) 2007-12-06
WO2001076627A1 (en) 2001-10-18
BR0109846A (pt) 2003-06-03
EP2011512A1 (en) 2009-01-07
PL358394A1 (en) 2004-08-09
CA2401836A1 (en) 2001-10-18
NO20024815D0 (no) 2002-10-04
EP1267925B1 (en) 2007-06-13
EP1267925B8 (en) 2007-08-29
EP1852128A1 (en) 2007-11-07
EP1818062A1 (en) 2007-08-15
EP1818062A3 (en) 2007-10-24
CN1420786A (zh) 2003-05-28
JP2003530357A (ja) 2003-10-14
CN101095952A (zh) 2008-01-02
CY1106794T1 (el) 2012-05-23
RU2002129510A (ru) 2004-03-27
RU2262952C2 (ru) 2005-10-27
DK1267925T3 (da) 2007-10-15

Similar Documents

Publication Publication Date Title
GB0008305D0 (en) Treatment of fungal infections
CY2019029I1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
IL172871A (en) Isolated human antibody or antigen-binding section, training linker, single-chain antibody molecule, polypeptide containing them and their use
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
DK1718677T3 (da) Monovalente antistoffragmenter egnede som terapeutiske midler
CY1119291T1 (el) Πολυσθενη αντισωματα και χρησεις για αυτα
ATE374214T1 (de) Monoklonaler anti-cd-40-antikörper
SI1546734T1 (sl) N-11 skrajšana amiloid beta monoklonska protitelesa, sestavki, postopki in uporaba
WO2003011899A3 (en) Antigenic polypeptides
IL206832A0 (en) Antibodies binding an 161p2f10b epitope and uses thereof
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
GB9806762D0 (en) Treatment and diagnosis of staphylococcal infections
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
AU2002217212A1 (en) Method for preparing a human monoclonal antibody, fragments thereof or antibodies comprising such fragments, resulting antibodies and use thereof
AU2001255537A1 (en) Monoclonal antibody antagonists for treating medical problems associated with d-amphetamine-like drugs
CY1109121T1 (el) Θεραπεια μυκητιασικων μολυνσεων
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
WO2003097663A3 (de) Immunogener, monoklonaler antikörper, der mindestens 2 verschiedene epitope ines tumor-assoziierten antigens aufweist
AU2001272529A1 (en) Monoclonal antibody against human cathepsin w
GB0121727D0 (en) Monoclonal antibodies
AU2002227175A1 (en) Anti-tenascin monoclonal antibody therapy for lymphoma
GB0017139D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)